Loading...
•
Sep 30
Journey Medical Q3 2025 Earnings Report
Journey Medical reported a revenue increase in Q3 2025 driven by strong Emrosi performance, though the company posted a net loss.
Key Takeaways
Journey Medical achieved strong year-over-year revenue growth in Q3 2025, largely fueled by the launch and commercial momentum of Emrosi. Despite higher revenues and improving margins, the company reported a net loss of $2.3M.
Revenue rose to $17.6 million, up 21% YoY due to Emrosi sales
Emrosi generated $4.9 million in net revenue during Q3
Gross margin improved sequentially to 67.4%
Adjusted EBITDA reached $1.7 million, up from $0.3 million in Q3 2024
Journey Medical
Journey Medical
Journey Medical Revenue by Segment
Revenue by Segment
Emrosi Revenue
CapyFin.com Forward Guidance
No formal financial guidance was provided, but the company emphasized Emrosi’s growth trajectory and operational leverage potential.
Positive Outlook
- Strong launch and growth of Emrosi with 146% increase in prescriptions QoQ
- Gross margin expansion over consecutive quarters
- Adjusted EBITDA turned positive year-over-year
- Cash position increased to $24.9 million
- Over 100 million commercial lives now covered for Emrosi
Challenges Ahead
- Net loss of $2.3 million reported for the quarter
- Operating loss of $1.5 million despite revenue growth
- No forward-looking revenue or profit guidance provided
- SG&A expenses rose due to Emrosi commercialization
- Gross margin declined YoY due to one-time favorable items in prior year